Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
Total Valuation
RAPT Therapeutics has a market cap or net worth of $178.59M. The enterprise value is $146.64M.
Market Cap$178.59M
Enterprise Value$146.64M
Share Statistics
RAPT Therapeutics has 16,536,085 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,536,085
Owned by Insiders1.61%
Owned by Institutions85.22%
Financial Efficiency
RAPT Therapeutics’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is -70.01%.
Return on Equity (ROE)-0.68
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-70.01%
Return on Capital Employed (ROCE)-0.71
Revenue Per Employee0.00
Profits Per Employee-1.94M
Employee Count67
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio3.73
Price to Fair Value0.34
Price to FCF-1.87
Price to Operating Cash Flow-6.09
PEG Ratio-0.25
Income Statement
In the last 12 months, RAPT Therapeutics had revenue of 0.00 and earned -129.87M in profits. Earnings per share was -3.19.
Revenue0.00
Gross Profit0.00
Operating Income-136.10M
Pretax Income-129.87M
Net Income-129.87M
EBITDA-126.33M
Earnings Per Share (EPS)-3.19
Cash Flow
In the last 12 months, operating cash flow was -108.63M and capital expenditures -60.00K, giving a free cash flow of -108.69M billion.
Operating Cash Flow-108.63M
Free Cash Flow-108.69M
Free Cash Flow per Share-6.57
Dividends & Yields
RAPT Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change-54.39%
50-Day Moving Average9.14
200-Day Moving Average9.90
Relative Strength Index (RSI)52.02
Average Volume (3m)117.96K
Important Dates
RAPT Therapeutics upcoming earnings date is Aug 7, 2025, Before Open (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
RAPT Therapeutics as a current ratio of 4.87, with Debt / Equity ratio of 2.16%
Current Ratio4.87
Quick Ratio4.87
Debt to Market Cap0.04
Net Debt to EBITDA1.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, RAPT Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
RAPT Therapeutics EV to EBITDA ratio is 0.80, with an EV/FCF ratio of 1.21.
EV to Sales0.00
EV to EBITDA0.80
EV to Free Cash Flow1.21
EV to Operating Cash Flow1.21
Balance Sheet
RAPT Therapeutics has $179.28M in cash and marketable securities with $3.83M in debt, giving a net cash position of -$175.44M billion.
Cash & Marketable Securities$179.28M
Total Debt$3.83M
Net Cash-$175.44M
Net Cash Per Share-$10.61
Tangible Book Value Per Share$4.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for RAPT Therapeutics is $25.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.33
Price Target Upside134.54% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-2.29%